Few data are available on the prevalence of fatigue among patients receiving anti-estrogenic treatment for breast cancer, though a relationship has been demonstrated between the use of the estrogen receptor antagonist tamoxifen and AROi and the occurrence of self-reported fatigue [34,35]. This evidence concerns the gene ESR1 and breast carcinoma.